簡易檢索 / 詳目顯示

研究生: 劉翠華
Tsui-Hua Liu
論文名稱: 抗漿細胞瘤抑制素單株抗體的製備與分析
Characterization of monoclonal antibodies against plasmacytoma
指導教授: 曾哲明
Tseng, Jer-Ming
學位類別: 碩士
Master
系所名稱: 生命科學系
Department of Life Science
畢業學年度: 83
語文別: 中文
論文頁數: 75
中文關鍵詞: 漿細胞瘤抑制素;單株抗體;巨噬細胞
英文關鍵詞: plasmacytoma inhibitor factor; monoclonal antiboody; macrophage
論文種類: 學術論文
相關次數: 點閱:199下載:0
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報
  • 巨噬細胞株 P388D1 可分泌抑制素抑制漿細胞瘤細胞株 MOPC-315 的生長
    並誘發細胞自戕現象。 本實驗製備抗漿細胞瘤抑制素單株抗體並分析其特
    性,隨後進一步以此單株抗體純化漿細胞瘤抑制素。P388D1 培養基上清液
    ,經 DEAE-Sephacel 離子交換色層分析,得到二群具有抑制活性的蛋白,
    分別稱之為 Peak 1,Peak 2。隨後以 Peak 1 及 Peak 2 免疫 Balb/c 老
    鼠,經脾臟細胞與骨髓瘤細胞株融合產生融合瘤之後,以中和 PIF 抑制活
    性的生物測試及酵素免疫分析法進行篩選, 最後篩選出 38 株製造抗漿細
    胞瘤抑制素單株抗體的融合瘤。其中以 Peak 1 和 Peak 2 一起免疫,獲
    得 2 株單株抗體;以 Peak 1 免疫,獲得 28 株單株抗體;以 Peak 2 免
    疫,獲得 8 株單株抗體。 CA5-1.23 ( gamma-1, lambda ; 效價為 3.27x
    10000﹚,CB7-1.1﹙ gamma-1,lambda;效價為 5.24x100000﹚,CB7-1.5﹙
    gamma-1,lambda;效價為 1.31x100000﹚,CB7-1.19﹙ gamma-1,lambda;效
    價為 1.31x100000﹚,EE6-2.2﹙gamma-1,kappa;效價為 5.24x100000﹚等
    五株抗體,進一步作西方點墨法分析,結果皆辨識 Peak 1 中之一分子量
    約 60KDa 的蛋白;CB2-2.18﹙ mu,kappa;效價為 1.31x100000﹚,作西方
    點墨法分析,結果辨識 Peak 1 中分子量約 60KDa、51KDa、50KDa、47KDa
    等四種蛋白。 在 P388D1 和 MOPC-315 共同培養情況下,加入此六株單株
    抗體,可中和 P388D1 對 MOPC-315 產生之抑制作用。 利用 CA5-1.23 單
    株抗體製備親和性色層分析管,進一步純化漿細胞瘤抑制素, 純化倍率為
    1045 倍,高純度之漿細胞瘤抑制素只需 0.625ng,便能抑制 MOPC-315 的
    生長。

    P388D1, macrophage-like cells secreted a plasmacytoma inhibitory
    factor (PIF) that suppressed the growth of MOPC-315 and induced
    apoptosis. The specific aim of this study was to prepared a panel
    of monoclonal antibodies that neutralized the activity of PIF.
    P388D1 culture supernatants were analyzed by a DEAE-Sephacel
    chromatography, and the plasmacytoma inhibitory activity was
    localized on two protein peaks designated as Peak 1 and Peak 2.
    Both Peak 1 and Peak 2 were used to immunize Balb/c mices,
    together and separately. The hybirdoma were prepared by fusing
    spleen cells with myeloma and were screened using both
    neutralization assay and ELISA. Among the 38 positive lines, 2
    lines were obtained from Peak 1 & Peak 2 immunization, 28 lines
    were obtained from Peak 1 immunization, 8 lines were obtained
    from Peak 2 immunization. CA5-1.23 (gamma-1,lambda,titer 3.27x
    10000), CB7-1.1(gamma-1,lambda,titer 5.24x100000), CB7-1.5(gamma-
    1,lambda,titer 1.31x100000), CB7-1.19 (gamma-1,lambda,titer 1.31x
    100000), EA6-2.2 (gamma-1,kappa,titer 5.24x100000),and CB2-2.18 (
    mu,kappa,titer 1.31x100000) were further used to preform Western
    blotting and neutralization assay. CA5-1.23, CB7-1.1, CB7-1.5,
    CB7-1.19, and EE6-2.2 detected a 60KDa protein among the proteins
    in Peak 1. However CB2-2.18 detected four proteins with the M.W.
    at 60KDa, 51KDa, 50KDa, 47KDa, respectively. In addition, all six
    monoclonal antibodies could partially block the P388D1-mediated
    tumoricidal activity against MOPC-315 plasmacytoma. The PIF was
    further purified using an immunoaffinity column prepared from
    CA5-1.23 coupling Affi-Gel 10. Approximately 1045-fold
    purification was achieved and the highly purified PIF showed
    strong inhibition against the growth of MOPC-315 plasmacytoma at
    a dose as low as 0.625ng.
    P388D1, macrophage-like cells secreted a plasmacytoma inhibitory

    無法下載圖示
    QR CODE